India Biosimilar Market to Witness a Healthy Growth During 2026-2035, Aided by the Growing Prevalence of Chronic Diseases Worldwide

The market in the region is being driven by the heightened prevalence of chronic diseases and ailments that are boosting the demand for biosimilars for efficient and cost-effective treatments. In 2020, with the advent of the COVID-19 outbreak worldwide, the demand for biosimilars witnessed a surge to aid in treating and managing COVID-19 related health issues. The growing investments by the market players in the development and trials of novel biosimilar solutions supported the market growth during the period. The growing public expenditure on the expansion and development of the healthcare infrastructure is expected to create new growth opportunities for the biosimilar industry. Furthermore, the growing government initiatives to promote the use of biosimilars over branded biologics are expected to significantly contribute to the market growth in the forecast period.

The growing collaborations among the leading players aimed at the development of advanced biosimilars to expand their product portfolio are expected to spearhead the market growth in the forecast years. For instance, in January 2018, Sandoz, a leading developer of biosimilars and a division of the Novartis Group (OTCMKTS: NVSEF), announced a collaboration with Biocon Limited, Asia’s biggest biopharmaceutical firm based in India, for the development, production, and c ommercialisation of a range of biosimilars among immunology and oncology patients across the globe. Furthermore, in March 2022, Biocon Biologics, a unit of Biocon Limited, announced to buy the biosimilar assets of its partner firm Viatris Inc. (NASDAQ: VTRS). This would help broaden Biocon’s market reach across North American and European markets.

Read more about this report - REQUEST FREE SAMPLE COPY IN PDF

Market Breakup by Molecule, Manufacturing Type, and Indication:

• The market is divided, based on molecule, into human growth hormone, insulin glargine, interferon, erythropoietin, monoclonal antibodies, and granulocyte colony stimulating factor (G-CSF), among others.
• On the basis of manufacturing type, the market can be distributed into in-house manufacturing and contract manufacturing.
• Based on indication, the industry is segregated into auto-immune diseases, blood disorder, diabetes, oncology, growth deficiency, and female infertility, among others.

Key Findings of the Report:

• The biosimilar industry in India is being driven by the increasing prevalence of chronic diseases and ailments.
• The growing government investments in the development of the healthcare infrastructure have significantly contributed to the market expansion.
• The increasing collaborations and the growing focus of pharmaceutical companies on biosimilar drugs over generic drugs are also aiding the industry growth.
• The growing investments by the leading market players in the development of novel biosimilars are further propelling the market growth.

Key Offerings of the Report:

• The EMR report gives an overview of the India market for biosimilar for the periods (2019-2025) and (2026-2035).
• The report also offers historical (2019-2025) and forecast (2026-2035) market information for the molecules, manufacturing types, indications, and regions of biosimilar.
• The report analyses the market dynamics, covering the key demand and price indicators in the market, along with providing an assessment of the SWOT and Porter’s Five Forces models.

Top Players:

The major players in the India biosimilar market are:

• Pfizer Inc.
• Eli Lilly and Company
• Celltrion Healthcare
• Viatris Inc. (Mylan)
• Novartis AG
• Samsung Bioepis Co. Ltd.
• Stada Arzneimittel AG
• Teva Pharmaceutical Industries Ltd.
• Intas Pharmaceutical Ltd.
• LG Life Sciences Inc.
• Biocon Limited
• Amgen Inc.
• Dr. Reddy's Laboratories
• Coherus Biosciences Inc.
• Biocad

The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.

About Us

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.

EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.

Contact Us

Expert Market Research
Website: www.expertmarketresearch.com
Email: [email protected]
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790